Genomic data offers correlation in abundance. Causation requires experimental proof at every step. Join insitro at #AASLD2025. On Monday, 1pm, Poster 4013: learn how platform integration of AI, patient-derived biology & staged validation narrow the gap for MASLD therapeutics.

We extended our collaboration w/ @bristolmyerssquibb.bsky.social to advance our #ALS target into AI-enabled #drugdiscovery. The next phase is w/ our ChemML™ platform, turning discoveries➡️medicines w/ AI-driven modeling, medicinal chemistry, & structural biology. www.insitro.com/news/insitro...

We’re @ #ASHG to share our work that uses high-content phenotypic data, genetics & AI/ML to unblock new biology.

@sominenihk.bsky.social presents work to identify a key gene as a clinical driver of #MASLD

@twsoare.bsky.social presents on #AMD & how we use OCT scans to better predict disease risk

We’re excited to announce a new collaboration with @elilillyandcompany.bsky.social to build next-gen #machinelearning models for small molecule design. www.insitro.com/news/insitro...

Gabriel blends biology & ML to drive small molecule #drugdevelopment. From melanoma research to a Master’s at UCL to presenting insitro’s KinDEL dataset @ ICML, his career advances drug discovery w/ scalable data & predictive modeling. Read his Meet the insitrocyte below. arxiv.org/abs/2410.08938

7️⃣ years of using AI differently. That means looking where others don’t. . . or can’t.

@keystonesymposia.bsky.social’s joint conference is coming up! insitro’s Director Max Salick will present at “The Digital Era in Neurodegeneration & Neuroinflammation” to share recent research & technological advances on our POSH platform. Learn more: www.keystonesymposia.org/conferences/...

Today insitro announces an exciting new collaboration with insighteyehub.bsky.social at Moorfields Eye Hospital, London, through the development of a novel #AI foundation model to identify and to support #drugdiscovery. Learn more: www.businesswire.com/news/home/20...

Join insitro CEO & founder Daphne Koller at WIRED Health in London Tuesday, March 18 as she takes the keynote stage! 📣 Daphne will be sharing an inside look at how insitro’s approach to #drugdiscovery is building a pipeline of high-conviction targets through #machinelearning, #AI & data at scale.

Thanks to the SFBT for including insitro CEO and founder Daphne Koller in their Newsmakers 100 list, recognizing the great partnerships and developments we announced with both
@elilillyandcompany.bsky.social and @bms-us.bsky.social in 2024. 🌟 Read more ➡️ www.bizjournals.com/sanfrancisco...

Our insitrocytes are the heartbeat of our shared vision. Together, as builders, scientists, engineers, we solve complex challenges every day, laser-focused on delivering better medicines for patients. Hear directly from some of our colleagues about how we work.
Visit www.insitro.com/people/.